Which has better earnings & valuation, TRVI or ABVX?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is TRVI or ABVX more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Abivax N/A -99.02% -70.26%

Does the media prefer TRVI or ABVX?

In the previous week, Abivax had 14 more articles in the media than Trevi Therapeutics. MarketBeat recorded 16 mentions for Abivax and 2 mentions for Trevi Therapeutics. Abivax's average media sentiment score of 0.95 beat Trevi Therapeutics' score of 0.63 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRVI or TGTX?

In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 2 articles in the media. TG Therapeutics' average media sentiment score of 1.16 beat Trevi Therapeutics' score of 0.63 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRVI or QGEN?

In the previous week, Qiagen had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Qiagen and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat Qiagen's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRAX or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Trevi Therapeutics N/A -24.53% -23.37%

Does the media favor PRAX or TRVI?

In the previous week, Praxis Precision Medicines had 9 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 2 mentions for Trevi Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.70 beat Trevi Therapeutics' score of 0.63 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRVI or IBRX?

In the previous week, ImmunityBio had 7 more articles in the media than Trevi Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat ImmunityBio's score of 0.42 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trevi Therapeutics (TRVI) Competitors

$18.65 +0.02 (+0.11%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$18.76 +0.11 (+0.59%)

As of 06/30/2026 07:59 PM Eastern

Compare

TRVI vs. ABVX, TGTX, QGEN, PRAX, and IBRX

Should you buy Trevi Therapeutics stock or one of its competitors? MarketBeat compares Trevi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevi Therapeutics include Abivax (ABVX), TG Therapeutics (TGTX), Qiagen (QGEN), Praxis Precision Medicines (PRAX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Trevi Therapeutics compare to Abivax?

Trevi Therapeutics (NASDAQ:TRVI) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Abivax had 14 more articles in the media than Trevi Therapeutics. MarketBeat recorded 16 mentions for Abivax and 2 mentions for Trevi Therapeutics. Abivax's average media sentiment score of 0.95 beat Trevi Therapeutics' score of 0.63 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics presently has a consensus price target of $22.90, suggesting a potential upside of 22.79%. Abivax has a consensus price target of $144.46, suggesting a potential upside of 8.37%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Trevi Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Trevi Therapeutics' return on equity of -24.53% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Abivax	N/A	-99.02%	-70.26%

Summary

Trevi Therapeutics beats Abivax on 10 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to TG Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Trevi Therapeutics currently has a consensus target price of $22.90, suggesting a potential upside of 22.79%. TG Therapeutics has a consensus target price of $58.60, suggesting a potential upside of 6.66%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
TG Therapeutics	$616.29M	13.65	$447.18M	$2.86	19.21

TG Therapeutics has a net margin of 65.95% compared to Trevi Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
TG Therapeutics	65.95%	88.73%	43.44%

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 2 articles in the media. TG Therapeutics' average media sentiment score of 1.16 beat Trevi Therapeutics' score of 0.63 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Trevi Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Trevi Therapeutics compare to Qiagen?

Trevi Therapeutics (NASDAQ:TRVI) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

In the previous week, Qiagen had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Qiagen and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat Qiagen's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Trevi Therapeutics currently has a consensus price target of $22.90, indicating a potential upside of 22.79%. Qiagen has a consensus price target of $43.15, indicating a potential upside of 10.20%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Trevi Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

Qiagen has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Qiagen	$2.09B	3.86	$424.88M	$1.91	20.50

Qiagen has a net margin of 19.16% compared to Trevi Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Qiagen	19.16%	14.40%	8.40%

Summary

Trevi Therapeutics and Qiagen tied by winning 8 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Trevi Therapeutics	N/A	-24.53%	-23.37%

In the previous week, Praxis Precision Medicines had 9 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 2 mentions for Trevi Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.70 beat Trevi Therapeutics' score of 0.63 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,091.69	-$303.27M	-$13.37	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Praxis Precision Medicines presently has a consensus price target of $569.63, suggesting a potential upside of 70.15%. Trevi Therapeutics has a consensus price target of $22.90, suggesting a potential upside of 22.79%. Given Praxis Precision Medicines' higher probable upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Praxis Precision Medicines has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Trevi Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Trevi Therapeutics compare to ImmunityBio?

Trevi Therapeutics (NASDAQ:TRVI) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Trevi Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
ImmunityBio	-606.15%	N/A	-59.53%

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ImmunityBio had 7 more articles in the media than Trevi Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat ImmunityBio's score of 0.42 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trevi Therapeutics has higher earnings, but lower revenue than ImmunityBio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
ImmunityBio	$113.29M	80.98	-$351.40M	-$0.85	N/A

Trevi Therapeutics currently has a consensus target price of $22.90, indicating a potential upside of 22.79%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 62.10%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Trevi Therapeutics beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.65B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-58.28	20.90	27.51	24.87
Price / Sales	N/A	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	13.04	8.75	11.01	6.54
Net Income	-$42.76M	$23.81M	$3.57B	$336.70M
7 Day Performance	7.03%	3.60%	2.31%	2.88%
1 Month Performance	33.69%	3.72%	1.38%	0.64%
1 Year Performance	227.19%	68.80%	36.70%	31.34%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	2.4353 of 5 stars	$18.65 +0.1%	$22.67 +21.5%	+241.0%	$2.65B	N/A	N/A	20
ABVX Abivax	1.9624 of 5 stars	$102.18 +4.8%	$130.08 +27.3%	+1,642.5%	$8.19B	N/A	N/A	61	Trending News Analyst Forecast Gap Up
TGTX TG Therapeutics	3.1137 of 5 stars	$51.83 +2.5%	$52.50 +1.3%	+52.7%	$7.95B	$700.35M	18.15	290	Positive News
QGEN Qiagen	3.4839 of 5 stars	$37.34 +0.3%	$44.98 +20.5%	-22.6%	$7.69B	$2.10B	19.50	5,654
PRAX Praxis Precision Medicines	3.5414 of 5 stars	$275.04 +6.9%	$572.72 +108.2%	+696.2%	$7.65B	$8.55M	N/A	110	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. ABVX, TGTX, QGEN, PRAX, and IBRX

How does Trevi Therapeutics compare to Abivax?

Summary

How does Trevi Therapeutics compare to TG Therapeutics?

Summary

How does Trevi Therapeutics compare to Qiagen?

Summary

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. ABVX, TGTX, QGEN, PRAX, and IBRX

How does Trevi Therapeutics compare to Abivax?

Does the media prefer TRVI or ABVX?

Do analysts rate TRVI or ABVX?

Which has more risk and volatility, TRVI or ABVX?

Which has better earnings & valuation, TRVI or ABVX?

Do institutionals and insiders hold more shares of TRVI or ABVX?

Is TRVI or ABVX more profitable?

Summary

How does Trevi Therapeutics compare to TG Therapeutics?

Do analysts rate TRVI or TGTX?

Which has more volatility & risk, TRVI or TGTX?

Which has better earnings and valuation, TRVI or TGTX?

Is TRVI or TGTX more profitable?

Do insiders & institutionals have more ownership in TRVI or TGTX?

Does the media prefer TRVI or TGTX?

Summary

How does Trevi Therapeutics compare to Qiagen?

Does the media prefer TRVI or QGEN?

Do institutionals & insiders believe in TRVI or QGEN?

Which has more risk and volatility, TRVI or QGEN?

Do analysts recommend TRVI or QGEN?

Which has higher earnings and valuation, TRVI or QGEN?

Is TRVI or QGEN more profitable?

Summary

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Do insiders and institutionals have more ownership in PRAX or TRVI?

Is PRAX or TRVI more profitable?

Does the media favor PRAX or TRVI?

Which has better valuation and earnings, PRAX or TRVI?

Do analysts rate PRAX or TRVI?

Which has more volatility and risk, PRAX or TRVI?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Which has more volatility and risk, TRVI or IBRX?

Is TRVI or IBRX more profitable?

Do insiders & institutionals believe in TRVI or IBRX?

Does the media refer more to TRVI or IBRX?

Which has stronger valuation & earnings, TRVI or IBRX?

Do analysts prefer TRVI or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools